Nimotuzumab in the Treatment of Inoperable Esophageal Tumors of Epithelial Origin

Table 3

Response evaluation in the new diagnosis stratum.

Response evaluation (N = 100)		Nimo + CT + RT		Nimo + CT		Nimo + RT		Nimo		Total
		No.	%	No.	%	No.	%	No.	%	No.	%
Response	Complete response (CR)	10	22.7	2	9.5	2	14.3	2	9.5	16	16.0
	Partial response (PR)	6	13.6	2	9.5	0	0.0	0	0.0	8	8.0
	Stable disease (SD)	2	4.5	0	0.0	1	7.1	2	9.5	5	5.0
	Progressive disease (PD)	7	15.9	4	19.0	2	14.3	2	9.5	15	15.0
	Not evaluated	19	43.2	13	61.9	9	64.3	15	71.4	56	56.0
Objective response	CR + PR	16	36.3	4	19.0	2	14.3	2	9.5	24	24.0
	SD + PD	9	20.4	4	19.0	3	21.4	4	19.0	20	20.0
	Not evaluated	19	43.2	13	61.9	9	64.3	15	71.4	56	56.0
Disease control	CR + PR + SD	18	40.8	4	19.0	3	21.4	4	19.0	29	29.0
	Progressive disease	7	15.9	4	19.0	2	14.3	2	9.5	15	15.0
	Not evaluated	19	43.2	13	61.9	9	64.3	15	71.4	56	56.0

Nimo: nimotuzumab, CT: chemotherapy, RT: radiotherapy.